Clinical trials: Narcolepsy Type 1
Narcolepsy Type 1
Temporal Interference Stimulation of Hypothalamus in Patients With Narcolepsy Type 1
Narcolepsy type 1 (NT1) is a chronic brain disorder caused by selective loss or dysfunction of orexin (hypocretin) neurons in the lateral hypothalamus, for which current pharmacological treatments offer limited efficacy.
- Trial name
- TINY (NCT07727239)
- Testing
- Active Temporal Interference Stimulation
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Xijing Hospital
Narcolepsy Type 1
A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)
Narcolepsy is a sleep disorder that disrupts a person's regular sleep-wake cycle. It causes extreme sleepiness during the day (called excessive daytime sleepiness [EDS]), where a person may fall asleep without warning.
- Trial name
- NCT07633301
- Testing
- TAK-360
- Where
- 18 sites in United States, Australia and 5 more
- Volunteers
- 92 people
- Sponsor
- Takeda
Narcolepsy Type 1 (NT 1)
Extended-release Sodium Oxybate in Children
The main objectives of this study are to determine the treatment preferences of children with narcolepsy type 1 between Extended-release sodium oxybate and Non-extended-release oxybates (Sodium oxybate or a medication with the…
- Trial name
- NCT06809803
- Testing
- Extended-release sodium oxybate, Non-extended-release oxybates
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Stanford University
Narcolepsy Type 1, Narcolepsy Type 2
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
Narcolepsy Type 1 (NT1) and Narcolepsy Type 2 (NT2) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness [EDS]).
- Trial name
- NCT07598708
- Testing
- cleminorexton
- Where
- 23 sites in United States
- Volunteers
- 222 people
- Sponsor
- Centessa Pharmaceuticals (UK) Limited
Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2)
A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy
The main aims of the study are: To check for side effects from TAK-994 and check what dose of TAK-994 participants can tolerate. To check what dose range provides adequate relief of narcolepsy symptoms.
- Trial name
- NCT04096560
- Testing
- TAK-994
- Where
- 78 sites in United States, Canada and 10 more
- Volunteers
- 97 people
- Sponsor
- Takeda
Narcolepsy Type 1 (NT 1), Hypersomnolence Disorder
Radar Sleep Monitoring in Type 1 Narcolepsy: Feasibility
This study aims to evaluate the clinical feasibility of a millimeter-wave radar sleep monitoring system in the diagnosis of Narcolepsy Type 1 (NT1).
- Trial name
- NCT07654803
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Sleep Paralysis, Narcolepsy Type 1
Meditation-Relaxation (MR Therapy) for Sleep Paralysis.
The aim of the study is to evaluate, with a small-scale pilot study, the efficacy of Meditation Relaxation therapy for Sleep Paralyses in patients with narcolepsy.
- Trial name
- MR_Therapy (NCT04483310)
- Testing
- MR therapy., breathing-distraction exercise
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Azienda Usl di Bologna
Hypersomnolence
Sleep/Wake State Assessment with Non-invasive Earbuds
This study is a within subject's assessment of whether a novel wearable technology, NextSense electroencephalography earbuds (EEGBuds), is able to detect differences in onset to sleep from wake versus in-laboratory, gold-standard…
- Trial name
- NCT05066009
- Testing
- NextSense EEG-enabled earbuds, Ellcie Healthy eyeglasses, Drug Holiday
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Emory University
Narcolepsy Type 1, Narcolepsy Type 2
Epidemiology of Narcolepsy Type 1 and Type 2 in Spain
The main purpose of this study is to find out how many people in Spain have been diagnosed with narcolepsy type 1 and type 2, and how many new participants are diagnosed each year.
- Trial name
- HYPNOS (NCT07299097)
- Testing
- No intervention
- Where
- 10 sites in Spain
- Volunteers
- 402 people
- Sponsor
- Takeda
Narcolepsy Type 1
Evaluation of the Effectiveness of a Physical Activity Program on the Severity of Narcolepsy
Narcolepsy Type 1 (NT1) is a rare chronic neurological disorder resulting from the selective loss of hypocretin neurons. Patients with NT1 suffer from excessive daytime sleepiness, disrupted nighttime sleep, and cataplexy…
- Trial name
- NARCOSPORT (NCT05460052)
- Testing
- Physical activity training program, Weekly phone call., Personalized training plan.
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Narcolepsy Type 1, Narcolepsy Type 2
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2)…
- Conditions
- Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
- Trial name
- NCT07096674
- Testing
- ORX750
- Where
- 24 sites in United States, Canada and 2 more
- Volunteers
- 90 people
- Sponsor
- Centessa Pharmaceuticals (UK) Limited
Narcolepsy Type 1, Hypersomnia
A Pilot Observational Study to Assess the Ability of Continuous 'Home' EEG to Accurately Diagnose Narcolepsy and Demonstrate Response to Treatment
The goal of this pilot observational study is to assess the ability of continuous 'home' EEG to accurately diagnose Narcolepsy in children and young people with hypersomnia.
- Trial name
- NCT05983731
- Volunteers
- 60 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Narcolepsy Type 1
Mentalizating in Adults Suffering from Narcolepsy Type 1.
The main objective is to examine the potential mentalization impairments affecting a population suffering from narcolepsy type 1.
- Trial name
- NARCOMENTAL (NCT06336057)
- Testing
- Mentalization
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Toulouse
Narcolepsy 1, Kleine-Levin Syndrome
Microglial Activation in Narcolepsy Type 1 and Kleine-Levin Syndrome: Positron Emission Tomography (PET) Study in [18F] DPA-714
Type 1 narcolepsy (NT1) is a chronic sleep disorder caused by the selective and irreversible loss of neurons from the hypothalamus, which synthesizes a neurotransmitter: hypocretin (Hcrt) / orexin.
- Trial name
- NARCOGLIE (NCT03754348)
- Testing
- PET scan with tracer injection [18F] DPA-714
- Where
- France
- Volunteers
- 78 people
- Sponsor
- University Hospital, Montpellier
Narcolepsy
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
The primary purpose of this study is to evaluate the optimal doses of E2086 compared to placebo in participants with narcolepsy for reduction of excessive daytime sleepiness (EDS) as assessed by Mean Sleep Latency (MSL) (measured…
- Trial name
- NCT07493265
- Testing
- E2086
- Where
- 57 sites in United States, Belgium and 8 more
- Volunteers
- 64 people
- Sponsor
- Eisai Inc.
Narcolepsy Type 1, Hypersomnolence
Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions
Mind wandering is a state in which attention turns away from the external environment or current task to focus on internal thoughts (past experiences, future events, planned actions...).
- Conditions
- Narcolepsy Type 1, Hypersomnolence, Idiopathic Hypersomnia
- Trial name
- NARCOWANDERING (NCT06457945)
- Testing
- ASRT, Questionnaires, Electrophysiological recordings
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Hospices Civils de Lyon